Insight Molecular director granted 32,331 shares

Arno Andrew reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 06/15/2026 - 06:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Arno Andrew reported acquisition or exercise transactions in this Form 4 filing.

Insight Molecular Diagnostics director Arno Andrew received an equity grant. He was awarded 32,331 shares of Common Stock at a price of $0.00 per share as a grant or award. These Restricted Stock Units vest at the next annual meeting of shareholders, subject to his continued service. Following the grant, he directly holds 168,885 shares and also has 7,804 shares held indirectly through investment LLCs where he has voting and disposition power.

Insider Trade Summary

Grant/Award: 32,331 shares

Grant/Award 1 txn

Insider Arno Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, no par value	32,331	$0.00	$0.00
Holding	Common Stock, no par value	--	--	--
Holding	Common Stock, no par value	--	--	--

Holdings After Transaction: Common Stock, no par value — 168,885 shares (Direct); Common Stock, no par value — 15,608 shares (Indirect, See footnote)

Holdings Before and After: Common Stock, no par value, 136,554 to 168,885 shares (Direct)

Footnotes (3)

1. F1. The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service from the date of grant until the vesting date.
2. F2. These shares of Common Stock are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and, in such capacity, has the right to vote and dispose of securities held by JBA, including the shares of Common Stock reported here.
3. F3. These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and, in such capacity, has the right to vote and dispose of securities held by MJA, including the shares of Common Stock reported here.

Key Figures

Stock grant size: 32,331 shares Grant price per share: $0.00 per share Direct holdings after grant: 168,885 shares +1 more

4 metrics

Stock grant size 32,331 shares Common Stock grant coded as acquisition (A)

Grant price per share $0.00 per share Reported transaction price for awarded shares

Direct holdings after grant 168,885 shares Total Common Stock directly owned following transaction

Indirect holdings 7,804 shares Common Stock held indirectly through investment LLCs

Key Terms

Restricted Stock Units, indirect, annual meeting of shareholders, right to vote and dispose

4 terms

Restricted Stock Units financial

"The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

indirect financial

"These shares of Common Stock are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA"

annual meeting of shareholders financial

"shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

right to vote and dispose financial

"has the right to vote and dispose of securities held by JBA, including the shares of Common Stock reported here"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Insight Molecular Diagnostics (IMDX) director Arno Andrew report on this Form 4?

Director Arno Andrew reported receiving a grant of 32,331 shares of Common Stock at $0.00 per share. The filing also shows his updated direct holdings and indirect holdings through investment LLCs where he has voting and disposition authority.

How many Insight Molecular Diagnostics (IMDX) shares did Arno Andrew receive in this grant?

He received 32,331 shares of Common Stock as a grant or award. The transaction was coded as an acquisition (A), indicating a compensation-related award rather than an open-market purchase, at a stated price of $0.00 per share.

When do Arno Andrew’s Restricted Stock Units in Insight Molecular Diagnostics (IMDX) vest?

The Restricted Stock Units vest on the date of the next annual meeting of shareholders. Vesting is conditioned on the director’s continued service from the grant date through that annual meeting, according to the footnote disclosure.

What are Arno Andrew’s direct share holdings in Insight Molecular Diagnostics (IMDX) after this Form 4?

After the reported grant, Arno Andrew directly owns 168,885 shares of Common Stock. This total includes the newly granted 32,331 shares and reflects his position immediately following the transaction date disclosed in the filing.

Does Arno Andrew have indirect ownership of Insight Molecular Diagnostics (IMDX) shares?

Yes. The filing shows 7,804 shares held indirectly and notes they are held by investment LLCs JBA Investments LLC and MJA Investments LLC. As manager of these entities, he has the right to vote and dispose of those securities.

Is Arno Andrew’s 32,331-share grant in Insight Molecular Diagnostics (IMDX) an open-market purchase?

No. The transaction is coded “A” and described as a grant, award, or other acquisition. It represents compensation-related equity rather than an open-market buy, with a reported price per share of $0.00 in the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arno Andrew

(Last) (First) (Middle)

C/O INSIGHT MOLECULAR DIAGNOSTICS INC.

2 INTERNATIONAL PLAZA, SUITE 510

(Street)

NASHVILLE TENNESSEE 37217

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Insight Molecular Diagnostics Inc. [ IMDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, no par value(1)	06/11/2026		A		32,331	A	$0	168,885	D
Common Stock, no par value								7,804	I	See footnote(2)
Common Stock, no par value								7,804	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service from the date of grant until the vesting date.

2. These shares of Common Stock are held by JBA Investments LLC ("JBA"). The Reporting Person is the Manager of JBA and, in such capacity, has the right to vote and dispose of securities held by JBA, including the shares of Common Stock reported here.

3. These shares of Common Stock are held by MJA Investments LLC ("MJA"). The Reporting Person is the Manager of MJA and, in such capacity, has the right to vote and dispose of securities held by MJA, including the shares of Common Stock reported here.

	/s/ Andrew Arno	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)